Scalable Biologics Production Trends: Featuring Omar Wahab Of Lonza — Breakthrough, Episode 250

In this episode, Dr. Corey Stanton speaks with Dr. Omar Wahab, Vice President of Bioprocessing at Lonza, about the strategic role of cell culture media in scalable biologics manufacturing.

As biologics pipelines expand across oncology, immunology and advanced therapies, upstream decisions are increasingly critical to manufacturing readiness, supply resilience and commercial success. Drawing on over 20 years of experience, Dr. Wahab explains how early formulation choices influence downstream productivity, product quality and cost of goods.

He emphasizes that media development should be treated as a core element of process design—not routine procurement—particularly as intensified platforms and higher cell densities heighten sensitivity to raw material variability.

The discussion also addresses pressures to accelerate clinical timelines while ensuring scalability and regulatory compliance. Dr. Wahab highlights the value of structured approaches like Design of Experiments in generating actionable insights and reducing reliance on trial-and-error.

He further underscores the need to align upstream innovation with real-world manufacturing, including scalable processes and sustainable sourcing. Non-GMP and GMP stages are key transition points where strong formulation strategies can reduce comparability risks and support supply continuity.

Looking ahead, tighter integration across functions and digital tools will be essential to improving decision-making and enabling success at commercial scale.